)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Prothena Corporation (PRTA) investor relations material
Prothena Corporation Evercore ISI 8th Annual HealthCONx Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Evercore ISI 8th Annual HealthCONx Conference summary4 Dec, 2025
Pipeline and program updates
Two phase III programs advancing: prasinezumab for early Parkinson's (with Roche) and coramitug for ATTR cardiomyopathy (with Novo), both with recent positive data and phase III initiations in late 2024.
Phase II Alzheimer's program targeting tau (with Bristol Myers Squibb) and phase I neurodegeneration program (X019) ongoing, with key data expected in 2027.
Unpartnered programs progressing, including PRX012 for Alzheimer's, with efforts to enhance blood-brain barrier penetration using transferrin technology.
Up to $105 million in clinical milestones anticipated in 2026 for coramitug enrollment; share repurchase program approved for 2026.
Additional data on CYTOPE and ALS program expected, following recent presentations.
Scientific and clinical insights
PRX012 shows robust amyloid reduction, with over 80% of patients amyloid negative at 18 months using subcutaneous monthly dosing.
ARIA rate for PRX012 is approximately 40%, with ongoing efforts to mitigate this effect, including exploring pre-symptomatic patient populations.
Transferrin-based brain shuttle technology may allow for a threefold dose reduction and potentially improved CNS distribution and ARIA profile.
FDA guidance may reduce preclinical requirements for novel molecular entities, with ongoing discussions about IND-enabling toxicology packages.
Fast-track status for tau-targeting phase II program reflects regulatory conviction in tau as a key Alzheimer's target.
Partnership and collaboration strategy
Strategic partnerships with Roche, Novo, and Bristol Myers Squibb drive late-stage programs, with active scientific and clinical collaboration.
Partner decisions to advance programs are based on rigorous internal criteria and recent compelling data, especially for prasinezumab and coramitug.
Support for partner programs includes scientific input and clinical trial execution, with more intensive involvement in early-stage studies.
Licensing and collaboration opportunities for transferrin-based anti-A beta antibodies depend on the strength of preclinical and clinical data.
Ongoing evaluation of deal value and timing for data disclosure to maximize partnership potential.
How does transferrin impact PRX012's ARIA risk?
What makes MTBR tau a compelling target?
Partner conviction for Phase 3 assets
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Prothena Corporation earnings date
Q4 202519 Feb, 2026
Next Prothena Corporation earnings date
Q4 202519 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery and development of novel therapies for diseases caused by protein dysregulation. The company's portfolio includes a range of investigational humanized antibodies and other therapeutic candidates targeting conditions such as AL amyloidosis, Parkinson's disease, ATTR amyloidosis, and Alzheimer's disease. Prothena's approach leverages insights into the biology of misfolded proteins to develop therapies aimed at changing the course of neurodegenerative and rare peripheral amyloid diseases. The company is headquartered in Dublin, Ireland, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage